[Impact of GP IIb/IIIa antagonists in interventional cardiology].
Scheller
B
B
Innere Medizin III, Kardiologie/Angiologie, Universität des Saarlandes, Homburg/Saar. bruno.scheller@uniklinik-saarland.de
Hennen
B
B
Böhm
M
M
Nickenig
G
G
D000077284:Abciximab; D000208:Acute Disease; D000787:Angina Pectoris / Q000188:drug therapy* / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D015607:Stents; D013577:Syndrome; D015912:Thrombolytic Therapy; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide; D000077284:Abciximab